ClinicalTrials.gg

Program

BI 3032950

A development code. Also written as “BI 3032950 intravenous (Part A)” and “BI 3032950 subcutaneous (Part B)”.

In Boehringer Ingelheim's pipeline, TREM-1 antagonist. Its studies are mostly in Colitis, Ulcerative, led by Boehringer Ingelheim.

Furthest: phase 2, since Oct 7, 20243 company-led studies, 1 open or runningNext primary completion: Jul 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim31 open or runningphase 2since Oct 7, 2024Aug 25, 2022Jul 30, 2027phase 2 · NCT06636656
  • Named in Boehringer Ingelheim’s own pipeline as BI 3032950, phase 2, as of Aug 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 25, 2022First study: phase 1 study in HealthyFirst studyNCT05518708 · 94 enrolled · Belgium
  2. Aug 3, 2023Phase 1 study in HealthyNCT05985200 · 40 enrolled · Belgium
  3. Oct 7, 2024Phase 2 study in Colitis, UlcerativeNCT06636656 · 80 planned · United States, Belgium, Czechia and more

Ahead

  1. Jul 30, 2027Primary completion: phase 2 study in Colitis, UlcerativeNCT06636656

TargetBeta

“TREM-1 antagonist”the company's pipeline, read by Claude · source

Other programs on TREM1

ProgramCompanyFurthest phaseStudies
ABBV-8736AbbViephase 23

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06636656Colitis, Ulcerative · United States, Belgium, Czechia and more2RecruitingJul 30, 202780
NCT05985200Healthy · Belgium1CompletedAug 19, 202440
NCT05518708Healthy · Belgium1CompletedSep 21, 202394

How it is read

Names in the registry

  • “BI 3032950”, 2 entries
  • “BI 3032950 intravenous (Part A)”, 1 entry
  • “BI 3032950 subcutaneous (Part B)”, 1 entry

Codes read as this program: BI3032950.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.